Second Line Trials

1. NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pre-treated With Pemetrexed

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT01098266

The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
Alberta
Cross Cancer Institute, Edmonton

Ontario
Princess Margaret Hospital, Toronto

2. LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT01685138

A Phase II, Multi-center, Single-arm Study of Oral LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer.
Ontario
London
Toronto
Oshawa

Saskatchewan
Regina
Saskatoon

Quebec
Montreal

3. A Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer(BIRCH)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02031458

This multicenter, single- arm study will evaluate the efficacy and safety of MPDL3280A in patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer. Patients will receive MPDL3280A 1200 mg intravenously every 3 weeks for a maximum of 16 cycles (or 12 months, whichever occurs first).
British Columbia
Vancouver

Ontario
Toronto
Oshawa
Ottawa

4. A Study of MPDL3280A Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Platinum Failure

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT01903993

This multicenter, open-label, randomized study will evaluate the efficacy and safety of MPDL3280A compared with docetaxel in patients with advanced or metastatic non-small cell lung cancer after platinum failure. Patients will be randomized to receive either MPDL3280A 1200 mg intravenously every 3 weeks or docetaxel 75 mg/m2 intravenously every 3 weeks. Treatment may be continued for a maximum of 16 cycles (or 12 months, whichever occurs first) in the absence of disease progression or unacceptable toxicity.
Quebec
Montreal
Laval

5. Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT01933932

The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor mutations of KRAS. This study will also assess the PK, safety, patient reported outcomes (PRO) and tolerability profile of the selumetinib/docetaxel combination, compared to placebo in combination with docetaxel.
Alberta
Edmonton

British Columbia
Kelowna
Surrey

Nova Scotia
Halifax

Ontario
Oshawa
Toronto

Saskatchewan
Regina
Saskatoon

Quebec
Montreal
Quebec City

6. Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT01905657

This study will compare two doses of MK-3475 versus docetaxel in participants with non-small cell lung cancer (NSCLC) who have experienced disease progression after platinum-containing systemic therapy. Participants will be assigned randomly to receive either Low Dose or High Dose MK-3475 every three weeks (Q3W), or docetaxel at 75 mg/m^2 Q3W.
Quebec
Kirkland

7. A Study of LY2835219 in Participants With Previously Treated Lung Cancer (JUNIPER)

ClinicalTrials.gov Identifier: NCT02152631

A Randomized Phase 3 Study of LY2835219 Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy.
Alberta
Calgary
Edmonton

British Columbia
Vancouver

Manitoba
Winnipeg

Ontario
Toronto

Quebec
Montreal

8. A Phase 2, Multicenter, Randomized Study of AP26113 (ALTA)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02094573

The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of AP26113 in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on therapy with crizotinib.
Ontario
Ottawa Hospital Cancer Centre, Ottawa
Princess Margaret Hospital, Toronto

9. Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

ClinicalTrials.gov Identifier: NCT02323126

A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer.
Ontario
Toronto

10. A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

ClinicalTrials.gov Identifier: NCT01970865

Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non-small cell lung cancer patients.
Alberta
Cross Cancer Institute, Edmonton

Ontario
Princess Margaret Hospital, Toronto

Quebec
Jewish General Hospital, Montreal
McGill University Hospital, Montreal
St. Mary’s Hospital, Montreal

11. Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer

ClinicalTrials.gov Identifier: NCT02337530

A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Cisplatin Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell lung cancer. The purpose of this study is to find out what effects a new drug, selumetinib, has on lung cancer when receiving standard chemotherapy with pemetrexed and cisplatin.
British Columbia
Vancouver Cancer Centre, Vancouver
Abbotsford Center, Abbotsford

Ontario
Cancer Centre of Southeastern Ontario, Kingston
Lakeridge Health, Oshawa
Lakeridge Cancer Center, Oshawa
Juravinski Cancer Center, Hamilton
Ottawa Hospital Cancer Center, Ottawa
Mount Sinai Hospital, Toronto
Princess Margaret Hospital, Toronto

Quebec
Hopital Notre-Dame, Montreal

New Brunswick
Saint John

12. Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02038647

This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to evaluate the efficacy and safety of alisertib, an Aurora A kinase inhibitor, in combination with paclitaxel compared with placebo + paclitaxel in patients with SCLC who have relapsed or did not respond to first line standard therapy.
Alberta
Edmonton

Ontario
Hamilton

Quebec
Greenfield Park

13. A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy

UPDATE: This study has been withdrawn.
 
ClinicalTrials.gov Identifier: NCT02152059

This study is being done to evaluate the good and bad effects of BIBF1120 in recurrent, platinum-sensitive small cell lung cancer patients and to see if BIBF1120 may or may not be more effective and better tolerated than standard therapy.
Alberta
Edmonton

14. Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 and Nab®-Paclitaxel Monotherapy as Second Line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer (abound2L)

ClinicalTrials.gov Identifier: NCT02250326

This is a Phase 2, randomized, open-label, multicenter study to assess the efficacy and safety of nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486, and nab-paclitaxel monotherapy as second-line treatment in subjects with advanced non-squamous NSCLC.
Quebec
Royal Victoria Hospital, Montreal

Ontario
Ottawa

15. A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451)

ClinicalTrials.gov Identifier: NCT02538666

The purpose of this study is to show that maintenance therapy with nivolumab, or nivolumab plus ipilimumab followed by nivolumab alone, will prolong Overall Survival and Progression Free Survival compared with placebo in subjects with extensive stage disease small cell lung cancer who have completed first line chemotherapy.
Alberta
Edmonton

Ontario
Oshawa
Windsor
Sudbury

16. A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02066636

A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen.
Quebec
Levis

17. Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell lung Cancer Patients

ClinicalTrials.gov Identifier: NCT02879760

This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with a platinum based chemotherapy.
Ontario
Juravinski Cancer Centre, Hamilton
Ottawa Hospital, Ottawa

18. Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001)

ClinicalTrials.gov Identifier: NCT02733250

The purpose of this study is to determine the optimal dose of nab-paclitaxel to be safely administered in combination with pembrolizumab in patients with advanced inoperable non-small cell lung cancer. The study is also aimed at evaluating the efficacy of the combination therapy.
Quebec
(CHUM) - Notre-Dame Hospital, Montreal
Jewish General Hospital, Montreal

19. S1400B Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

ClinicalTrials.gov Identifier: NCT02785913

This phase II trial studies how well taselisib (GDC-0032) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the phosphoinositide 3-kinase (PI3K) biomarker. PI3K can cause tumour cells to grow more quickly. Taselisib may decrease the activity of PI3K and may be able to shrink tumours.
Ontario
Juravinski Cancer Centre, Hamilton
Ottawa Hospital and Cancer Center, Ottawa
Princess Margaret Hospital, Toronto

Saskatchewan
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon

20. Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

ClinicalTrials.gov Identifier: NCT02785952

This randomized phase III trial compares nivolumab with ipilimumab and nivolumab alone in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a "non-match" sub-study that includes all screened patients not eligible for a biomarker-driven sub-study. Monoclonal antibodies, such as nivolumab and ipilimumab, may be able to shrink tumours. It is not yet known whether nivolumab works better with or without ipilimumab in treating patients with squamous cell lung cancer.
Ontario
Princess Margaret Hospital, Toronto

Saskatchewan
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon

21. Docetaxel With or Without MLN1117 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer

ClinicalTrials.gov Identifier: NCT02393209

A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer.
Alberta
Edmonton

Ontario
Toronto

22. A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)

ClinicalTrials.gov Identifier: NCT02913443

This is a Phase I, open-label, multicenter study designed to assess the safety and tolerability of RO7051790 in participants with relapsed ED SCLC. This dose escalation and expansion study plans to determine the maximum tolerated dose and/or optimal biological dose as a recommended Phase 2 dose for RO7051790, based on the safety, tolerability, pharmacokinetic and pharmacodynamic profiles observed after oral administration of RO7051790.
Ontario
Toronto
Ottawa

23. ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients (ALTA-1L)

ClinicalTrials.gov Identifier: NCT02737501

A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in ALK-positive Advanced Lung Cancer Patients.
Ontario
Princess Margaret Cancer Centre, Toronto